Sanofi launches global first with dengue immunization program in the Philippines

4 April 2016

French pharma giant Sanofi (Euronext: SAN) has started the world’s first dengue immunization program in the Philippines.

At a major launch event on Monday hosted by the Department of Health (DoH) of the Philippines, which is working with Sanofi Pasteur, the company’s vaccines global business unit, details about the country’s plan to vaccinate one million public school children were shared.

In December 2015, Sanofi Pasteur’s tetravalent dengue vaccine, Dengvaxia (CYD-TDV), was approved for use in people from nine to 45 years of age for the prevention of dengue fever caused by all four serotypes, in the Philippines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK